AnaptysBio Inc
F:AN6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AnaptysBio Inc
F:AN6
|
US |
|
Soditech SA
PAR:SEC
|
FR |
|
N
|
New Oriental Education & Technology Group Inc
HKEX:9901
|
CN |
|
China Mobile Ltd
HKEX:80941
|
CN |
|
F
|
Flutter Entertainment PLC
SWB:PPB
|
IE |
|
E
|
eGain Corp
LSE:0IFM
|
US |
|
A
|
Aurinia Pharmaceuticals Inc
F:IKAP
|
CA |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
US |
|
Bluestone Resources Inc
F:IX9D
|
CA |
|
LNA Sante SA
PAR:LNA
|
FR |
|
Nufarm Ltd
ASX:NUF
|
AU |
|
FirstEnergy Corp
NYSE:FE
|
US |
|
P
|
Petroleo Brasileiro SA Petrobras
DUS:PJXC
|
BR |
|
Airbus SE
PAR:AIR
|
NL |
|
S
|
Sembcorp Industries Ltd
F:SBOA
|
SG |
|
A
|
American International Group Inc
XHAM:AINN
|
US |
|
V
|
Veolia Environnement SA
DUS:VVD
|
FR |
|
T
|
Teradyne Inc
LSE:0LEF
|
US |
|
F
|
freenet AG
XHAM:FNTN
|
DE |
|
WD-40 Co
NASDAQ:WDFC
|
US |
|
V
|
Vicat SA
XBER:4HM
|
FR |
|
S
|
Swiss Re AG
XBER:SR9
|
CH |
|
B
|
Bukit Sembawang Estates Ltd
XMUN:B1W1
|
SG |
|
Ateme SA
PAR:ATEME
|
FR |
AnaptysBio Inc
AnaptysBio is a biotechnology company that develops antibody-based medicines for immune and inflammatory diseases. It spends its time finding and testing antibodies that can turn down harmful immune activity in conditions such as autoimmune disorders. Its work is aimed at doctors and patients who need new treatment options, and its drugs are still in the development and approval process rather than sold like ordinary medicines. The company makes money in two main ways. It can earn payments from partners that use its antibody discovery work, including upfront fees, milestone payments, and royalties if partnered drugs succeed. It can also make money later from selling its own approved medicines, if any of its internal drug candidates reach the market. What makes AnaptysBio different is that it is both a drug developer and a discovery partner. Instead of relying only on one commercial product, it builds a pipeline of immune-focused antibody programs and also licenses some of its science to larger drug companies. That gives it a business model tied to both long-term drug development and outside collaboration deals.
AnaptysBio is a biotechnology company that develops antibody-based medicines for immune and inflammatory diseases. It spends its time finding and testing antibodies that can turn down harmful immune activity in conditions such as autoimmune disorders. Its work is aimed at doctors and patients who need new treatment options, and its drugs are still in the development and approval process rather than sold like ordinary medicines.
The company makes money in two main ways. It can earn payments from partners that use its antibody discovery work, including upfront fees, milestone payments, and royalties if partnered drugs succeed. It can also make money later from selling its own approved medicines, if any of its internal drug candidates reach the market.
What makes AnaptysBio different is that it is both a drug developer and a discovery partner. Instead of relying only on one commercial product, it builds a pipeline of immune-focused antibody programs and also licenses some of its science to larger drug companies. That gives it a business model tied to both long-term drug development and outside collaboration deals.
